Make Pharma Content MLR-Ready Faster with Oyasin AI
Oyasin AI reviews claims, evidence, visuals, safety information, and layout to help teams prepare stronger, cleaner, and more MLR-ready content faster.
Multimodal Content Review
Analyze claims, visuals, tables, charts, citations, and safety information together instead of reviewing each element separately.
Explainable AI Feedback
Generate clear, traceable comments that help teams understand why a claim may be unsupported, overstated, incomplete, or potentially misleading.
Your Data Stays Yours
Oyasin AI is designed to protect sensitive pharma content with secure document handling, access controls, and workflows that keep your data private.
Regulated content review is slow, fragmented, and difficult to scale
In pharma, compliance risk is rarely limited to one sentence. A claim may look acceptable on its own but become risky when combined with a visual, graph, headline, missing limitation, weak citation, or small safety disclosure. Because many teams still rely on manual review cycles, scattered comments, and disconnected reference checks, the process often leads to:
Common Pain Points
- Repeated revision rounds
- Incomplete reference packs
- Inconsistent reviewer comments
- Limited traceability across versions
- Difficulty reviewing text, images, charts, and citations together
- Increased review time and cost
How Oyasin AI Works
Three simple steps to prepare stronger, more compliant content before MLR review.
Upload the Content
Upload a slide deck, sales aid, brochure, website copy, congress poster, email, or other regulated asset.
Our Special MRIE engine Reviews the Context
Our specialized MRIE engine analyzes text, visuals, charts, tables, citations, safety language, and layout position.
Receive An Explainable Report
Teams receive flagged risks, evidence gaps, suggested revisions, and traceable explanations to support faster review preparation.
MLR-Ready Content
Deliver cleaner, more consistent materials ready for faster Medical, Legal, and Regulatory review.
What we Heard from Industry
Through customer discovery conversations with pharmaceutical professionals, we consistently heard the same challenges and strong interest in AI-assisted pre-MLR review workflows.
Medical Affairs & Commercial Teams
Identified Veeva-based review workflows as a major bottleneck and expressed strong interest in AI-assisted pre-review, automated compliance screening, reviewer summaries, and improved global content management.
Regulatory & Medical Communications
Highlighted the value of linking claims, visuals, and supporting evidence into a single review workflow to improve review quality and consistency.
Regulatory Consulting
Recognized the importance of automated claim–evidence validation and pre-MLR screening to reduce compliance risk and revision cycles.
Commercial Review Teams
Emphasized the need for greater consistency across global promotional review processes and saw value in structured AI-assisted compliance review.
Healthcare Technology
Shared positive feedback on the concept, highlighting how an AI-assisted compliance platform could simplify regulatory review workflows and reduce manual effort.
